Abstract
Introduction: Layer-by-layer (LbL) nanoparticles consist of a versatile drug delivery technique, for targeted and controlled delivery. The Doxorubicin (DRC) is being widely used for treatment of pancreatic cancer (PCR). The present study was performed to develop and evaluation LbL nanoparticles (NP’s) of DRC to provide controlled and targeted delivery for effective treatment of PCR.
 Materials and Method: A liposomal based polymeric pH sensitive NP’s were prepared by utilizing LbL techniques. The NP’s were composed lipids, poly (b-amino ester) (PAE) and hyaluronic acid (HAC). The physiochemical properties of DRC-LbL NPs was evaluated such as particle size, zeta potential, percent entrapment efficiency (%EE), loading of drug and In-vitro drug release behavior. The surface morphology of LbL NP’s was evaluated by scanning electronic microscopy (SEM). The in vitro release of DRC-LbL-NP’s was determined by using Dialysis technique at pH 5 and 7.
 Results: Results showed that developed DRC-LbL NP’s having average particle size of 182.94 + 4.11 nm, zeta potential (ZP) of -42.78± 3.2mV, higher drug entrapment efficiency (EE) of 74.94±3.45. The in-vitro drug release from DRC-LbL NP’s exhibited sustained release pattern and it was triggered by lower pH. The surface morphology of developed DRC-LbL NP’s exhibited smooth and uniform particle size in nano range. The results from in-vitro drug release showed that there was significant difference in amount of DRC release in both pH media. In phosphate buffer pH 7.4 the total amount of DRC release was found to be 44.82 % after 48 hour of study whereas in pH 5.0 it was recorded 98.24% after 48 hours.
 Conclusion: The results from present study conclude that DRC-LbL NPs might be a promising candidate for the effective treatment of pancreatic cancer.
 Keywords: Layer-by-layer, Nanoparticles, Doxorubicin, Controlled delivery, Targeted Delivery
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.